Technical Analysis for PRTA - Prothena Corporation plc

Grade Last Price % Change Price Change
D 23.215 1.02% 0.24
PRTA closed up 6.24 percent on Friday, May 14, 2021, on 55 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical PRTA trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Down 3 Days in a Row Weakness 6.24%
Down 4 Days in a Row Weakness 6.24%
Oversold Stochastic Weakness 6.24%
MACD Bearish Centerline Cross Bearish 5.17%
Stochastic Reached Oversold Weakness 5.17%
Earnings Movers Other 5.17%
Down 3 Days in a Row Weakness 5.17%
Lower Bollinger Band Touch Weakness 5.17%
Older End-of-Day Signals for PRTA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% 27 minutes ago
Down 3% about 1 hour ago
Down 2 % about 1 hour ago
Down 1% about 1 hour ago
Rose Above Previous Day's High 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prothena Corporation plc Description

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biology Diseases Antibodies Neuroscience Alzheimer's Disease Parkinson's Disease Neurological Disorders Psychiatric Diagnosis Dementia Amyloid Amyotrophic Lateral Sclerosis Neurodegeneration Aging Associated Diseases Treatment Of Alzheimer's Disease Frontotemporal Dementia Histopathology Lewy Body Dementia

Is PRTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.6599
52 Week Low 9.25
Average Volume 371,254
200-Day Moving Average 15.91
50-Day Moving Average 24.07
20-Day Moving Average 24.23
10-Day Moving Average 23.70
Average True Range 1.68
ADX 12.92
+DI 20.77
-DI 22.39
Chandelier Exit (Long, 3 ATRs ) 22.68
Chandelier Exit (Short, 3 ATRs ) 26.40
Upper Bollinger Band 27.39
Lower Bollinger Band 21.08
Percent B (%b) 0.3
BandWidth 26.06
MACD Line -0.35
MACD Signal Line 0.06
MACD Histogram -0.4051
Fundamentals Value
Market Cap 917.39 Million
Num Shares 39.9 Million
EPS -2.10
Price-to-Earnings (P/E) Ratio -10.95
Price-to-Sales 601.55
Price-to-Book 2.15
PEG Ratio 0.80
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.81
Resistance 3 (R3) 25.63 24.51 25.34
Resistance 2 (R2) 24.51 23.78 24.60 25.18
Resistance 1 (R1) 23.74 23.34 24.12 23.92 25.03
Pivot Point 22.62 22.62 22.81 22.71 22.62
Support 1 (S1) 21.85 21.89 22.24 22.04 20.93
Support 2 (S2) 20.73 21.45 20.82 20.78
Support 3 (S3) 19.96 20.73 20.62
Support 4 (S4) 20.15